Initial public offering

Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock

Retrieved on: 
Wednesday, February 10, 2021
U.S. Securities and Exchange Commission, Initial public offering, Prospectus, Registration statement, Financial markets, Corporate finance, Stock market, Financial economics, SEC filings, Red herring prospectus

The closing of the offering is expected to occur on or aboutFebruary 12, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or aboutFebruary 12, 2021, subject to the satisfaction of customary closing conditions.
  • Cassava Sciences intends to use the net proceeds, if any, from this offering for working capital and general corporate purposes, including development of simufilam, the Companys lead drug candidate for the treatment of Alzheimers disease.
  • The offering will be made only by means of a prospectus supplement that forms a part of the registration statement.
  • A prospectus supplement and accompanying base prospectus relating to the shares of common stock being offered will be filed with the SEC.

Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares

Retrieved on: 
Wednesday, February 10, 2021
Financial markets, Finance, Corporate finance, American depositary receipt, Underwriting, ADSS, Stock market, Initial public offering

LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering of 34,500,000 American Depositary Shares (ADSs) at a public offering price of $2.90 per ADS.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the pricing of an underwritten public offering of 34,500,000 American Depositary Shares (ADSs) at a public offering price of $2.90 per ADS.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $100.1million.
  • In addition, Mereo has granted the underwriters a30-dayoption to purchase up to 5,175,000 additional ADSs at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about February 12, 2021, subject to the satisfaction of customary closing conditions.

Limbach Holdings Prices Public Offering of Common Stock

Retrieved on: 
Wednesday, February 10, 2021
Other Construction & Property, Commercial Building & Real Estate, Construction & Property, Building Systems, Financial markets, Finance, Financial economics, Corporate finance, Initial public offering, Stock market, Underwriting, Public offering, Stock, Limbach

In addition, Limbach has granted the underwriter a 30-day option to purchase up to 267,525 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Limbach has granted the underwriter a 30-day option to purchase up to 267,525 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds to Limbach from the public offering, before deducting underwriting discounts and offering expenses payable by Limbach, are expected to be approximately $21.4 million, assuming the underwriters option is not exercised.
  • Limbach intends to use the net proceeds from the public offering for general corporate purposes, which may include, without limitation, working capital and growth capital.
  • 333-252929) also relating to the public offering of the shares of common stock described above was filed with the SEC on February 10, 2021 pursuant to Rule 462(b) and was effective upon filing.

Babcock & Wilcox Enterprises Announces Pricing of Common Stock Offering

Retrieved on: 
Wednesday, February 10, 2021
Coal, Manufacturing, Energy, Engineering, Utilities, Financial markets, Finance, Stock market, Financial economics, Corporate finance, Initial public offering, Actuarial science, Underwriting, Public offering, Offering, Babcock & Wilcox, Stock

The Company has granted the underwriter a 30-day option to purchase up to an additional 3,846,154 of its common stock sold in the proposed offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • The Company has granted the underwriter a 30-day option to purchase up to an additional 3,846,154 of its common stock sold in the proposed offering at the public offering price, less underwriting discounts and commissions.
  • B. Riley Securities, Inc., is serving as the lead book-running manager for the offering.
  • Such forward looking statements include, but are not limited to, statements regarding the Company's public offering of common stock and intended use of net proceeds.
  • Headquartered in Akron, Ohio, Babcock & Wilcox Enterprises is a global leader in energy and environmental technologies and services for the power and industrial markets.

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

Retrieved on: 
Wednesday, February 10, 2021
Initial public offering, Finance, Financial economics, Money, ADSS, Underwriting, Public offering, Stock market

The aggregate gross proceeds from the ADS Offering are expected to be $20.1 million, before deducting the underwriting discounts and commissions and offering expenses payable by the Company.

Key Points: 
  • The aggregate gross proceeds from the ADS Offering are expected to be $20.1 million, before deducting the underwriting discounts and commissions and offering expenses payable by the Company.
  • The offering is expected to close on or about February 12, 2021, subject to satisfaction of customary closing conditions.
  • In connection with the ADS Offering, Biophytis has granted the underwriter a 30-day option to purchase up to 180,000 additional ADSs at the initial public offering price, less underwriting discounts and commissions (the Option).
  • Biophytis ADSs have been approved for listing on the Nasdaq Capital Market under the ticker symbol BPTS and are expected to begin trading on February 10, 2021 at 10 a.m., Eastern Time.

Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth

Retrieved on: 
Wednesday, February 10, 2021
Financial markets, Finance, Financial economics, Stock market, Initial public offering, 73rd United States Congress, U.S. Securities and Exchange Commission, Euronext, Security, Public offering, Securities Act, Forward-looking statement

This trading halt will remain effective until a new communication is released by the Company.

Key Points: 
  • This trading halt will remain effective until a new communication is released by the Company.
  • The company's ordinary shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.
  • The securities of Biophytis will be registered under the Securities Act, and Biophytis intends to conduct a public offering in the United States.

Hardbacon Announces Its Intent to Go Public in 2021

Retrieved on: 
Wednesday, February 10, 2021
Montreal, Initial public offering, Geography of Canada

MONTREAL, QC, Feb. 10, 2021 /PRNewswire/ --Hardbacon, a personal finance application used by more than 25,000 Canadians, has announced its intention to go public in 2021.

Key Points: 
  • MONTREAL, QC, Feb. 10, 2021 /PRNewswire/ --Hardbacon, a personal finance application used by more than 25,000 Canadians, has announced its intention to go public in 2021.
  • Hardbacon raised more than $1 million through its first two rounds on the regulated GoTroo and FrontFundr platforms.
  • "Having proved our concept to thousands of satisfied users, now is the time for us to pour fuel on the fire," said Hardbacon CEO Julien Brault.
  • "This IPO will allow Hardbacon to accelerate its growth and pursue strategic acquisitions."

Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market

Retrieved on: 
Wednesday, February 10, 2021
Initial public offering, Finance, Financial economics, Money, ADSS, Underwriting, Public offering, Stock market

The aggregate gross proceeds from the ADS Offering are expected to be $20.1 million, before deducting the underwriting discounts and commissions and offering expenses payable by the Company.

Key Points: 
  • The aggregate gross proceeds from the ADS Offering are expected to be $20.1 million, before deducting the underwriting discounts and commissions and offering expenses payable by the Company.
  • The offering is expected to close on or about February 12, 2021, subject to satisfaction of customary closing conditions.
  • In connection with the ADS Offering, Biophytis has granted the underwriter a 30-day option to purchase up to 180,000 additional ADSs at the initial public offering price, less underwriting discounts and commissions (the Option).
  • Biophytis ADSs have been approved for listing on the Nasdaq Capital Market under the ticker symbol BPTS and are expected to begin trading on February 10, 2021 at 10 a.m., Eastern Time.

Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth

Retrieved on: 
Wednesday, February 10, 2021
Financial markets, Finance, Financial economics, Stock market, Initial public offering, 73rd United States Congress, U.S. Securities and Exchange Commission, Euronext, Security, Public offering, Securities Act, Forward-looking statement

This trading halt will remain effective until a new communication is released by the Company.

Key Points: 
  • This trading halt will remain effective until a new communication is released by the Company.
  • The company's ordinary shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).
  • The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis.
  • The securities of Biophytis will be registered under the Securities Act, and Biophytis intends to conduct a public offering in the United States.

Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules

Retrieved on: 
Wednesday, February 10, 2021
Initial public offering, Prospectus, U.S. Securities and Exchange Commission, Shelf registration, Finance, Financial economics, Financial markets, Registration statement, Stock market, SEC filings, Red herring prospectus, Regulation S-K

The offering is expected to close on or about February 12, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about February 12, 2021, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $35.0 million, before deducting the placement agents fees and other offering expenses payable by the Company.
  • The shares described above are being offered and sold in this offering pursuant to a shelf registration statement on Form S-3 (File No.
  • A final prospectus supplement and accompanying prospectus relating to the ordinary shares being offered will be filed with the SEC.